109844-92-0

Basic information

• Product Name: N-(4-chlorophenyl)-5-nitrofuran-2-carboxamide
• Synonyms: N-(4-chlorophenyl)-5-nitrofuran-2-carboxamide
• CAS NO: 109844-92-0
• Molecular Weight: 266.641
• Mol File: 109844-92-0.mol

Chemical Properties

• Melting Point: 181 °C
• Boiling Point: 328.2±37.0 °C(Predicted)
• Density: 1.524±0.06 g/cm3(Predicted)
• CAS DataBase Reference: N-(4-chlorophenyl)-5-nitrofuran-2-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-chlorophenyl)-5-nitrofuran-2-carboxamide(109844-92-0)
• EPA Substance Registry System: N-(4-chlorophenyl)-5-nitrofuran-2-carboxamide(109844-92-0)

Safety Data

• Hazardous Substances Data: 109844-92-0(Hazardous Substances Data)

Upstream product

• 25084-14-4 5-nitrofuran-2-carboxylic chloride 
• 106-47-8 4-chloro-aniline 
• 645-12-5 5-nitro-2-furoic acid 

Relevant articles and documents

Diarylamide compound and application thereof

The invention discloses a use of a diarylamide compound with a structure shown as a formula (I), and a pharmaceutically acceptable salt thereof in the preparation of a medicine serving as a urea transporter inhibitor, and the novel diarylamide compound. T

Optimization of N-benzyl-5-nitrofuran-2-carboxamide as an antitubercular agent

The optimization campaign for a nitrofuran antitubercular hit (N-benzyl-5-nitrofuran-2-carboxamide; JSF-3449) led to the design, synthesis, and biological profiling of a family of analogs. These compounds exhibited potent in vitro antitubercular activity (MIC = 0.019–0.20 μM) against the Mycobacterium tuberculosis H37Rv strain and low in vitro cytotoxicity (CC50 = 40–>120 μM) towards Vero cells. Significant improvements in mouse liver microsomal stability and mouse pharmacokinetic profile were realized by introduction of an α α-dimethylbenzyl moiety. Among these compounds, JSF-4088 is highlighted due to its in vitro antitubercular potency (MIC = 0.019 μM) and Vero cell cytotoxicity (CC50 > 120 μM). The findings suggest a rationale for the continued evolution of this promising series of antitubercular small molecules.

A class of 5-nitro-2-furancarboxylamides with potent trypanocidal activity against Trypanosoma brucei in vitro

Recently, the World Health Organization approved the nifurtimox- eflornithine combination therapy for the treatment of human African trypanosomiasis, renewing interest in nitroheterocycle therapies for this and associated diseases. In this study, we have synthesized a series of novel 5-nitro-2-furancarboxylamides that show potent trypanocidal activity, ～1000-fold more potent than nifurtimox against in vitro Trypanosoma brucei with very low cytotoxicity against human HeLa cells. More importantly, the most potent analogue showed very limited cross-resistance to nifurtimox-resistant cells and vice versa. This implies that our novel, relatively easy to synthesize and therefore cheap, 5-nitro-2-furancarboxylamides are targeting a different, but still essential, biochemical process to those targeted by nifurtimox or its metabolites in the parasites. The significant increase in potency (smaller dose probably required) has the potential for greatly reducing unwanted side effects and also reducing the likelihood of drug resistance. Collectively, these findings have important implications for the future therapeutic treatment of African sleeping sickness.